Overview

Publication Portfolio

Peer-reviewed publications in biostatistics, clinical trials, machine learning, cancer genomics, and precision oncology. Research in AI, adaptive trial design, RNA-seq, and tumor subtyping.

Work spans clinical trials, genomics, machine learning, and epigenomics, with service on the Nature Medicine Statistical Advisory Panel (2024–) and as Associate Editor for Annals of Applied Statistics (2023–) and Statistical Methods in Medical Research.

Featured Publications

The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy

Cancer Cell (2026)

Describes the ARPA-H ADAPT platform trial infrastructure for metastatic breast cancer, integrating adaptive Bayesian designs, real-time biomarker monitoring, and AI-driven decision support across multiple cancer centers.

Efficient computation of high-dimensional penalized piecewise constant hazard random effects models

Statistics in Medicine (2025)

Developed scalable methods for survival analysis with high-dimensional random effects, enabling multi-center clinical studies with complex correlation structures.

DNA mutational profiling in colorectal cancer reveals racial disparities

Journal of Clinical Oncology (2024)

Profiled clinically-relevant mutations in CRC patients receiving standard-of-care therapies in CALGB 80405, uncovering outcome differences and racial disparities in mutation distributions.

Deeply-learned generalized linear models with missing data

Journal of Computational and Graphical Statistics (2024)

Co-led with David Lim to adapt deep learning for incomplete EHRs, informing ARPA-H ADAPT eligibility and toxicity modeling.

Publications by Theme

Use the search box below to find publications by keyword, or browse by research theme.

Research Themes

Clinical Trials

2026

  1. The ADAPT learning cancer treatment system: ARPA-H’s initiative to revolutionize cancer therapy
    Andrea H Bild, Michelle C Sangar, Jasmine A McQuerry, Trey Ideker, Scott Kopetz, and 15 more authors
    Cancer Cell, 2026

2024

  1. JCO
    DNA mutational profiling in patients with colorectal cancer treated with standard of care reveals differences in outcome and racial distribution of mutations
    Federico Innocenti, Wancen Mu, Xueping Qu, Fang-Shu Ou, Omar Kabbarah, and 4 more authors
    Journal of Clinical Oncology, 2024
  2. Purity independent subtyping of tumors (PurIST) pancreatic cancer classifier: analytic validation of a 16-RNA expression signature distinguishing basal and classical subtypes
    Yan Li, Jason D Merker, Rachana Kshatriya, Dimitri G Trembath, Ashley B Morrison, and 4 more authors
    The Journal of Molecular Diagnostics, 2024
  3. ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.
    Jose Pablo Leone, Kathryn Jean Ruddy, Naim Rashid, Sharon H Giordano, Gaorav P Gupta, and 11 more authors
    2024

2022

  1. Purity independent subtyping of tumors (purist), a platform and sample type independent single sample classifier for treatment decision making in pancreatic cancer
    Jen Jen Yeh, Richard Moffitt, and Naim Ur Rashid
    2022

2021

  1. Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer
    Susan Tsai, Erkut Borazanci, Margaret Gulley, Naim Rashid, Jason Merker, and 8 more authors
    Cancer Research, 2021
  2. Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer.
    Susan Tsai, Erkut Borazanci, Margaret Gulley, Naim Rashid, Jason Merker, and 8 more authors
    CANCER RESEARCH, 2021

2020

  1. CCR
    Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer
    Naim U Rashid, Xianlu L Peng, Chong Jin, Richard A Moffitt, Keith E Volmar, and 14 more authors
    Clinical Cancer Research, 2020
Penalized Mixed Models & High-Dimensional Inference

2025

  1. Efficient Computation of High‐Dimensional Penalized Piecewise Constant Hazard Random Effects Models
    Hillary M Heiling, Naim U Rashid, Quefeng Li, Xianlu L Peng, Jen Jen Yeh, and 1 more author
    Statistics in Medicine, 2025

2024

  1. glmmpen: High dimensional penalized generalized linear mixed models
    Hillary M Heiling, Naim U Rashid, Quefeng Li, and Joseph G Ibrahim
    The R journal, 2024
  2. Efficient computation of high-dimensional penalized generalized linear mixed models by latent factor modeling of the random effects
    Hillary M Heiling, Naim U Rashid, Quefeng Li, Xianlu L Peng, Jen Jen Yeh, and 1 more author
    Biometrics, 2024
  3. Differential transcript usage analysis incorporating quantification uncertainty via compositional measurement error regression modeling
    Amber M Young, Scott Van Buren, and Naim U Rashid
    Biostatistics, 2024

2023

  1. Estimating cell type composition using isoform expression one gene at a time
    Hillary M Heiling, Douglas R Wilson, Naim U Rashid, Wei Sun, and Joseph G Ibrahim
    Biometrics, 2023

2020

  1. Modeling between-study heterogeneity for improved replicability in gene signature selection and clinical prediction
    Naim U Rashid, Quefeng Li, Jen Jen Yeh, and Joseph G Ibrahim
    Journal of the American Statistical Association, 2020
  2. Differential transcript usage analysis incorporating quantification uncertainty via compositional measurement error regression modeling
    Scott Van Buren, and Naim Rashid
    bioRxiv, 2020

2019

  1. Improved detection of epigenomic marks with mixed-effects hidden markov models
    Pedro L Baldoni, Naim U Rashid, and Joseph G Ibrahim
    Biometrics, 2019
  2. Supplemental Material for “Modeling Between-Study Heterogeneity for Improved Replicability in Gene Signature Selection and Clinical Prediction”
    Naim U Rashid, Quefeng Li, Jen Jen Yeh, and Joseph G Ibrahim
    2019

2017

  1. A statistical model to assess (allele-specific) associations between gene expression and epigenetic features using sequencing data
    Naim U Rashid, Wei Sun, and Joseph G Ibrahim
    The annals of applied statistics, 2017

2014

  1. Some statistical strategies for DAE-seq data analysis: variable selection and modeling dependencies among observations
    Naim Rashid, Wei Sun, and Joseph G Ibrahim
    Journal of the American Statistical Association, 2014
Cancer Genomics & Multi-Omic Integration

2025

  1. Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy
    Akram Yazdani, Heinz-Josef Lenz, Gianluigi Pillonetto, Raul Mendez-Giraldez, Azam Yazdani, and 18 more authors
    Communications Medicine, 2025
  2. Tumor-intrinsic kinome landscape of pancreatic cancer reveals new therapeutic approaches
    Yi Xu, Xianlu L Peng, Michael P East, Ian C McCabe, Grace C Stroman, and 16 more authors
    Cancer discovery, 2025
  3. Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)
    Aranzazu Fernandez-Martinez, Maki Tanioka, Sung Gwe Ahn, Paola Zagami, Tomás Pascual, and 18 more authors
    Annals of Oncology, 2025
  4. Cross-platform comparison of gene expression-based cancer molecular subtyping reveals discrepancies with exome capture methods
    Jaewon J Lee, Mohammed Aldakkak, Ashley B Morrison, Sam Z Thalji, Xianlu L Peng, and 6 more authors
    NPJ Precision Oncology, 2025
  5. Defining the MYC-regulated transcriptome and kinome that support KRAS-and ERK-dependent growth of pancreatic cancer
    Priya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, Kristina Drizyte-Miller, Jennifer E Klomp, and 19 more authors
    Science Signaling, 2025
  6. Abstract B100: Spatial relationships between tumor subtypes and tumor-promoting CAFs with clinical implications
    Xianlu Laura Peng, Ian McCabe, Elena Kharitonova, Ryan Zhao, Changfei Luan, and 15 more authors
    Cancer Research, 2025
  7. Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets
    Brooke M Felsheim, Aranzazu Fernandez-Martinez, Cheng Fan, Adam D Pfefferle, Michele C Hayward, and 7 more authors
    NPJ Breast Cancer, 2025
  8. Baseline and adaptive activated kinome profiling identifies PTK6 as a mediator of resistance to vemurafenib and dabrafenib but not encorafenib in BRAFV600-mutant metastatic melanoma
    Steve P Angus, Naim U Rashid, Andrew J Walther, David L Corcoran, Steven D Rhodes, and 15 more authors
    Cancer Research, 2025
  9. Platform and sample type independent single sample classifier for treatment decision making in pancreatic ductal adenocarcinoma cancer
    Jen Jen Yeh, Richard Moffitt, and Naim Ur Rashid
    2025
  10. Targeting pancreatic cancer stroma with vitamin D normalizes survival between fibroblast subtypes
    JJ Lee, P Chan, C Luan, EV Kharitonova, NU Rashid, and 3 more authors
    HPB, 2025

2024

  1. Tumor intrinsic subtypes and gene expression signatures in early-stage ERBB2/HER2-positive breast cancer: a pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials
    Aranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, Tomás Pascual, Katherine A Hoadley, and 16 more authors
    JAMA oncology, 2024
  2. JCO
    DNA mutational profiling in patients with colorectal cancer treated with standard of care reveals differences in outcome and racial distribution of mutations
    Federico Innocenti, Wancen Mu, Xueping Qu, Fang-Shu Ou, Omar Kabbarah, and 4 more authors
    Journal of Clinical Oncology, 2024
  3. Determination of permissive and restraining cancer-associated fibroblast (DeCAF) subtypes
    Xianlu Laura Peng, Elena V Kharitonova, Yi Xu, Joseph F Kearney, Changfei Luan, and 18 more authors
    bioRxiv, 2024
  4. Purity independent subtyping of tumors (PurIST) pancreatic cancer classifier: analytic validation of a 16-RNA expression signature distinguishing basal and classical subtypes
    Yan Li, Jason D Merker, Rachana Kshatriya, Dimitri G Trembath, Ashley B Morrison, and 4 more authors
    The Journal of Molecular Diagnostics, 2024
  5. Tumor-intrinsic and cancer-associated fibroblast subtypes independently predict outcomes in pancreatic cancer
    Jaewon J Lee, Joseph F Kearney, Hannah E Trembath, Arthi Hariharan, Michelle E LaBella, and 9 more authors
    Annals of surgery, 2024
  6. Baseline pancreatic cancer CAF subtype determines response to neoadjuvant chemotherapy
    J Lee, Y Dave, P Chan, C Luan, E Kharitonova, and 5 more authors
    PANCREAS, 2024
  7. Development of DeCAF for CAF subtyping in patient tumors
    X Peng, E Kharitonova, I Mccabe, J Kearney, J Lee, and 11 more authors
    PANCREAS, 2024
  8. Abstract A042: Clinical classification of cancer-associated fibroblast subtypes predicts prognosis and treatment response
    Xianlu L Peng, Elena V Kharitonova, Ian C McCabe, Changfei Luan, Ryan T Zhao, and 17 more authors
    Cancer Research, 2024
  9. Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines
    Matthew E Berginski, Madison R Jenner, Chinmaya U Joisa, Gabriela Herrera Loeza, Brian T Golitz, and 6 more authors
    PeerJ, 2024
  10. Platform and sample type independent single sample classifier for treatment decision making in pancreatic ductal adenocarcinoma cancer
    Jen Jen Yeh, Richard Moffitt, and Naim Ur Rashid
    2024
  11. Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in HER2+ early-breast cancer (EBC)
    Aranzazu Fernandez-Martinez, Maki Tanioka, Sung Gwe Ahn, Paola Zagami, Tomas Pascual, and 17 more authors
    CANCER RESEARCH, 2024
  12. Combination of tumor and CAF subtypes better predict response to neoadjuvant therapy in pancreatic cancer
    Jaewon Lee, Joseph Kearney, Priscilla Chan, Elena Kharitonova, Arthi Hariharan, and 8 more authors
    ANNALS OF SURGICAL ONCOLOGY, 2024
  13. Molecular subtyping of pancreatic cancers using commercial sequencing platforms-a cautionary tale
    JJ Lee, S Thalji, AB Morrison, M Aldakkak, XL Peng, and 9 more authors
    HPB, 2024

2023

  1. Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials
    Aranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, Paolo Nuciforo, Naim U Rashid, and 14 more authors
    JAMA oncology, 2023
  2. Sub-Cluster Identification through Semi-Supervised Optimization of Rare-Cell Silhouettes (SCISSORS) in single-cell RNA-sequencing
    Jack R Leary, Yi Xu, Ashley B Morrison, Chong Jin, Emily C Shen, and 5 more authors
    Bioinformatics, 2023
  3. Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model
    Luke A Torre-Healy, Ryan R Kawalerski, Ki Oh, Lucie Chrastecka, Xianlu L Peng, and 4 more authors
    Communications Biology, 2023
  4. Association of PIK3CA mutation with pathologic complete response and outcome by hormone receptor status and intrinsic subtype in early-stage ERBB2/HER2-positive breast cancer
    Paola Zagami, Aranzazu Fernandez-Martinez, Naim U Rashid, Katherine A Hoadley, Patricia A Spears, and 3 more authors
    JAMA Network Open, 2023
  5. RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling
    Antje Schaefer, Richard G Hodge, Haisheng Zhang, G Aaron Hobbs, Julien Dilly, and 15 more authors
    Science signaling, 2023
  6. Abstract PD18-04: Prognostic implications of PIK3CA mutation by hormone receptor status and intrinsic subtype in early stage HER2-positive breast cancer: a correlative analysis from CALGB 40601
    Paola Zagami, Aranzazu Fernandez-Martinez, Naim U Rashid, Katherine A Hoadley, Patty Spears, and 2 more authors
    Cancer Research, 2023
  7. Impact of race and age on intrinsic subtype distribution and treatment decisions in metastatic breast cancer: Preliminary analysis of HARMONY (LCCC1829).
    Joannie M Ivory, Naim Rashid, Paola Zagami, Charles M Perou, Katherine Elizabeth Reeder-Hayes, and 1 more author
    2023

2022

  1. Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity
    Bhalchandra Mirlekar, Yan Wang, Sirui Li, Mi Zhou, Sarah Entwistle, and 10 more authors
    Cell reports Medicine, 2022
  2. Functional and biological heterogeneity of KRASQ61 mutations
    Minh V Huynh, G Aaron Hobbs, Antje Schaefer, Mariaelena Pierobon, Leiah M Carey, and 16 more authors
    Science signaling, 2022
  3. Tumor immunogenomic features determine outcomes in patients with metastatic colorectal cancer treated with standard-of-care combinations of bevacizumab and cetuximab
    Federico Innocenti, Akram Yazdani, Naim Rashid, Xueping Qu, Fang-Shu Ou, and 7 more authors
    Clinical Cancer Research, 2022
  4. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay
    DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, and 8 more authors
    Annals of Oncology, 2022
  5. Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials.
    Aranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, Tomas Pascual, Katherine A Hoadley, and 15 more authors
    2022
  6. Methods and compositions for prognostic and/or diagnostic subtyping of pancreatic cancer
    Richard Moffitt, Jen Jen Yeh, and Naim Ur Rashid
    2022
  7. Efficient detection and classification of epigenomic changes under multiple conditions
    Pedro L Baldoni, Naim U Rashid, and Joseph G Ibrahim
    Biometrics, 2022
  8. Purity independent subtyping of tumors (purist), a platform and sample type independent single sample classifier for treatment decision making in pancreatic cancer
    Jen Jen Yeh, Richard Moffitt, and Naim Ur Rashid
    2022

2021

  1. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
    DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, and 11 more authors
    Annals of Oncology, 2021
  2. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
    J Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, Priya S Hibshman, Devon R Blake, and 13 more authors
    Journal of Biological Chemistry, 2021
  3. FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
    Steven P Angus, Timothy J Stuhlmiller, Gaurav Mehta, Samantha M Bevill, Daniel R Goulet, and 25 more authors
    NPJ breast cancer, 2021
  4. Gene-expression based subtyping of pancreatic ductal adenocarcinoma
    Richard Moffitt, Jen Jen Yeh, and Naim Ur Rashid
    2021
  5. Compression of quantification uncertainty for scRNA-seq counts
    Scott Van Buren, Hirak Sarkar, Avi Srivastava, Naim U Rashid, Rob Patro, and 1 more author
    Bioinformatics, 2021
  6. Clinical application of next-generation sequencing in recurrent glioblastoma
    Daniel Zeitouni, Michael P Catalino, Jordan Wise, Sean McCabe, Kathryn Pietrosimone, and 2 more authors
    Onco, 2021
  7. Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer
    Susan Tsai, Erkut Borazanci, Margaret Gulley, Naim Rashid, Jason Merker, and 8 more authors
    Cancer Research, 2021
  8. Sub-Cluster Identification through Semi-Supervised Optimization of Rare-cell Silhouettes (SCISSORS) in Single-Cell Sequencing
    Jack Leary, Yi Xu, Ashley Morrison, Chong Jin, Emily C Shen, and 4 more authors
    bioRxiv, 2021
  9. Reply to:‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’by D. Fabrizio et al.
    Daniel James McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, and 8 more authors
    Annals of Oncology, 2021
  10. Kinome state is predictive of cell viability in pancreatic cancer tumor and stroma cell lines
    Matthew E Berginski, Madison R Jenner, Chinmaya U Joisa, Silvia G Herrera Loeza, Brian T Golitz, and 6 more authors
    BioRxiv, 2021
  11. 120MO Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials
    A Fernandez-Martinez, T Pascual, B Singh, P Nuciforo, KA Hoadley, and 9 more authors
    Annals of Oncology, 2021
  12. Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer.
    Susan Tsai, Erkut Borazanci, Margaret Gulley, Naim Rashid, Jason Merker, and 8 more authors
    CANCER RESEARCH, 2021
  13. Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer
    J Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, Devon R Blake, Priya S Hibshman, and 13 more authors
    bioRxiv, 2021
  14. Metadata record for the manuscript: FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
    Steven P Angus, Timothy J Stuhlmiller, Gaurav Mehta, Samantha M Bevill, Daniel R Goulet, and 25 more authors
    (No Title), 2021

2020

  1. CCR
    Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer
    Naim U Rashid, Xianlu L Peng, Chong Jin, Richard A Moffitt, Keith E Volmar, and 14 more authors
    Clinical Cancer Research, 2020
  2. B cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer
    Bhalchandra Mirlekar, Daniel Michaud, Samuel J Lee, Nancy P Kren, Cameron Harris, and 12 more authors
    Cancer immunology research, 2020
  3. A P53-independent DNA damage response suppresses oncogenic proliferation and genome instability
    Katerina D Fagan-Solis, Dennis A Simpson, Rashmi J Kumar, Luciano G Martelotto, Lisle E Mose, and 8 more authors
    Cell reports, 2020
  4. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy
    Matthew B Lipner, Xianlu L Peng, Chong Jin, Yi Xu, Yanzhe Gao, and 10 more authors
    JCI insight, 2020
  5. INNV-17. NEXT GENERATION SEQUENCING IMPACTS OUTCOMES IN RECURRENT PRIMARY GLIOBLASTOMA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
    Daniel Zeitouni, Michael Catalino, Jordan Wise, Kathryn Pietrosimone, Sean McCabe, and 2 more authors
    Neuro-Oncology, 2020
  6. Epigrahmm–epigenomic r-based analysis with hidden Markov models
    Pedro Baldoni, Naim U Rashid, and Joseph G Ibrahim
    F1000Research, 2020

2019

  1. Genetic determinants of cellular addiction to DNA polymerase theta
    Wanjuan Feng, Dennis A Simpson, Juan Carvajal-Garcia, Brandon A Price, Rashmi J Kumar, and 7 more authors
    Nature communications, 2019
  2. GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer
    Samantha M Bevill, Jose F Olivares-Quintero, Noah Sciaky, Brian T Golitz, Darshan Singh, and 9 more authors
    Molecular Cancer Research, 2019
  3. Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): Novel mutated genes and their effect on response to therapy (Alliance)
    F Innocenti, N Rashid, M Wancen, F-S Ou, X Qu, and 6 more authors
    Annals of Oncology, 2019
  4. Multi-omic dissection of oncogenically active epiproteomes identifies drivers of proliferative and invasive breast tumors
    John A Wrobel, Ling Xie, Li Wang, Cui Liu, Naim Rashid, and 6 more authors
    IScience, 2019
  5. Improved detection of epigenomic marks with mixed-effects hidden markov models
    Pedro L Baldoni, Naim U Rashid, and Joseph G Ibrahim
    Biometrics, 2019

2018

  1. KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism
    Angelina V Vaseva, Devon R Blake, Thomas SK Gilbert, Serina Ng, Galen Hostetter, and 16 more authors
    Cancer cell, 2018
  2. Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues
    Yanyan Yang, Ogun Adebali, Gang Wu, Christopher P Selby, Yi-Ying Chiou, and 4 more authors
    In Proceedings of the National Academy of Sciences, 2018
  3. Stromal content is correlated with tissue site, contrast retention, and survival in pancreatic adenocarcinoma
    Robert J Torphy, Zhen Wang, Aisha True-Yasaki, Keith E Volmar, Naim Rashid, and 5 more authors
    JCO precision oncology, 2018
  4. Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer.
    Samantha M Bevill, Noah Sciaky, Brian T Golitz, Naim U Rashid, Jon S Zawistowski, and 1 more author
    MOLECULAR CANCER RESEARCH, 2018
  5. Abstract B34: Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer
    Samantha M Bevill, Noah Sciaky, Brian T Golitz, Naim U Rashid, Jon S Zawistowski, and 1 more author
    Molecular Cancer Research, 2018
  6. Relationship between body mass index (BMI) and gene expression profiles of cervical cancer in the cancer genome atlas (TCGA) project
    Arthur-Quan Tran, Stephanie Adele Sullivan, Sean Doyle McCabe, Naim Rashid, and Victoria L Bae-Jump
    Gynecologic Oncology, 2018

2017

  1. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex
    Jon S Zawistowski, Samantha M Bevill, Daniel R Goulet, Timothy J Stuhlmiller, Adriana S Beltran, and 20 more authors
    Cancer discovery, 2017
  2. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer
    Amanda ED Van Swearingen, Maria J Sambade, Marni B Siegel, Shivani Sud, Robert S McNeill, and 12 more authors
    Neuro-oncology, 2017
  3. Kinome profiling identifies druggable targets for novel human cytomegalovirus (HCMV) antivirals
    Kyle C Arend, Erik M Lenarcic, Heather A Vincent, Naim Rashid, Eric Lazear, and 7 more authors
    Molecular & Cellular Proteomics, 2017
  4. A statistical model to assess (allele-specific) associations between gene expression and epigenetic features using sequencing data
    Naim U Rashid, Wei Sun, and Joseph G Ibrahim
    The annals of applied statistics, 2017

2016

  1. Mammalian Period represses and de-represses transcription by displacing CLOCK–BMAL1 from promoters in a Cryptochrome-dependent manner
    Yi-Ying Chiou, Yanyan Yang, Naim Rashid, Rui Ye, Christopher P Selby, and 1 more author
    In Proceedings of the National Academy of Sciences, 2016
  2. Metabolic reprogramming through fatty acid transport protein 1 (FATP1) regulates macrophage inflammatory potential and adipose inflammation
    Amy R Johnson, Yuanyuan Qin, Alyssa J Cozzo, Alex J Freemerman, Megan J Huang, and 16 more authors
    Molecular metabolism, 2016
  3. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
    Rao H Prabhala, Mariateresa Fulciniti, Dheeraj Pelluru, Naim Rashid, Andreea Nigroiu, and 16 more authors
    Leukemia, 2016
  4. Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project
    Dario R Roque, Liza Makowski, Ting-Huei Chen, Naim Rashid, D Neil Hayes, and 1 more author
    Gynecologic oncology, 2016

2015

  1. Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma
    Richard A Moffitt, Raoud Marayati, Elizabeth L Flate, Keith E Volmar, S Gabriela Herrera Loeza, and 13 more authors
    Nature genetics, 2015
  2. Functional and clinical impact of splicing factor dysregulation in multiple myeloma
    Mariateresa Fulciniti, Mehmet Kemal Samur, Naim Ur Rashid, Rajya Lakshmi Bandi, Manoj Bhasin, and 3 more authors
    Blood, 2015

2014

  1. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
    Niccolo Bolli, Hervé Avet-Loiseau, David C Wedge, Peter Van Loo, Ludmil B Alexandrov, and 30 more authors
    Nature communications, 2014
  2. Differential and limited expression of mutant alleles in multiple myeloma
    Naim U Rashid, Adam S Sperling, Niccolo Bolli, David C Wedge, Peter Van Loo, and 13 more authors
    Blood, The Journal of the American Society of Hematology, 2014
  3. Some statistical strategies for DAE-seq data analysis: variable selection and modeling dependencies among observations
    Naim Rashid, Wei Sun, and Joseph G Ibrahim
    Journal of the American Statistical Association, 2014
  4. Alternative splicing is a frequent event and impacts clinical outcome in myeloma: a large RNA-seq data analysis of newly-diagnosed myeloma patients
    Naim Rashid, Stephane Minvielle, Florence Magrangeas, Mehmet Kemal Samur, Alice Clynen, and 10 more authors
    Blood, 2014
  5. Frequent Igh fusion transcripts with clinical impact in multiple myeloma
    Alice Cleynen, Raphael Szalat, Mehmet Kemal Samur, Naim Rashid, Giovanni Parmigiani, and 2 more authors
    Blood, 2014
  6. Functional and Clinical Relevance of Splicing Factor SRSF1 in Multiple Myeloma (MM)
    Mariateresa Fulciniti, Manoj Bhasin, Mehmet Kemal Samur, Rajya Lakshmi Bandi, Naim Rashid, and 6 more authors
    Blood, 2014
  7. Ongoing spontaneous DNA damage and the role of aberrant epigenome in multiple myeloma
    Maria Gkotzamanidou, Masood Shammas, Vassilis L Souliotis, Weihua Song, Jagannath Pal, and 6 more authors
    Blood, 2014

2013

  1. Bone marrow microenvironment affects the pathogenesis of multiple myeloma through downregulation of alternative splicing factor FOX2 in myeloma cells
    Weihua Song, Chaolin Zhang, Yiguo Hu, Maria Gkotzamanidou, Parantu Shah, and 13 more authors
    Blood, 2013

2012

  1. An integrated encyclopedia of DNA elements in the human genome.
    BE Bernstein, E Birney, I Dunham, ED Green, C Gunter, and 1 more author
    Nature, 2012

2011

  1. ZINBA integrates local covariates with DNA-seq data to identify broad and narrow regions of enrichment, even within amplified genomic regions
    Naim U Rashid, Paul G Giresi, Joseph G Ibrahim, Wei Sun, and Jason D Lieb
    Genome biology, 2011
Machine Learning for Precision Oncology

2026

  1. The ADAPT learning cancer treatment system: ARPA-H’s initiative to revolutionize cancer therapy
    Andrea H Bild, Michelle C Sangar, Jasmine A McQuerry, Trey Ideker, Scott Kopetz, and 15 more authors
    Cancer Cell, 2026

2025

  1. Unsupervised Imputation of Non-Ignorably Missing Data Using Importance-Weighted Autoencoders
    David K Lim, Naim U Rashid, Junier B Oliva, and Joseph G Ibrahim
    Statistics in Biopharmaceutical Research, 2025

2024

  1. Deeply learned generalized linear models with missing data
    David K Lim, Naim U Rashid, Junier B Oliva, and Joseph G Ibrahim
    Journal of Computational and Graphical Statistics, 2024
  2. Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines
    Matthew E Berginski, Madison R Jenner, Chinmaya U Joisa, Gabriela Herrera Loeza, Brian T Golitz, and 6 more authors
    PeerJ, 2024
  3. Supplementary Materials for Unsupervised Imputation of Non-ignorably Missing Data Using Importance-Weighted Autoencoders
    David K Lim, Naim U Rashid, Junier B Oliva, and Joseph G Ibrahim
    2024

2023

  1. Sub-Cluster Identification through Semi-Supervised Optimization of Rare-Cell Silhouettes (SCISSORS) in single-cell RNA-sequencing
    Jack R Leary, Yi Xu, Ashley B Morrison, Chong Jin, Emily C Shen, and 5 more authors
    Bioinformatics, 2023
  2. Supporting Information for Deeply-Learned Generalized Linear Models with Missing Data
    David K Lim, Naim U Rashid, Junier B Oliva, and Joseph G Ibrahim
    2023

2021

  1. High-dimensional precision medicine from patient-derived xenografts
    Naim U Rashid, Daniel J Luckett, Jingxiang Chen, Michael T Lawson, Longshaokan Wang, and 6 more authors
    Journal of the American Statistical Association, 2021
  2. Model-based feature selection and clustering of RNA-seq data for unsupervised subtype discovery
    David K Lim, Naim U Rashid, and Joseph G Ibrahim
    The annals of applied statistics, 2021
  3. Compression of quantification uncertainty for scRNA-seq counts
    Scott Van Buren, Hirak Sarkar, Avi Srivastava, Naim U Rashid, Rob Patro, and 1 more author
    Bioinformatics, 2021
  4. Handling non-ignorably missing features in electronic health records data using importance-weighted autoencoders
    David K Lim, Naim U Rashid, Junier B Oliva, and Joseph G Ibrahim
    arXiv preprint arXiv:2101.07357, 2021
  5. Sub-Cluster Identification through Semi-Supervised Optimization of Rare-cell Silhouettes (SCISSORS) in Single-Cell Sequencing
    Jack Leary, Yi Xu, Ashley Morrison, Chong Jin, Emily C Shen, and 4 more authors
    bioRxiv, 2021
  6. Kinome state is predictive of cell viability in pancreatic cancer tumor and stroma cell lines
    Matthew E Berginski, Madison R Jenner, Chinmaya U Joisa, Silvia G Herrera Loeza, Brian T Golitz, and 6 more authors
    BioRxiv, 2021

2020

  1. Supporting Information for Model-based Feature Selection and Clustering of RNA-seq Data for Unsupervised Subtype Discovery
    David K Lim, Naim U Rashid, and Joseph G Ibrahim
    2020

2019

  1. High dimensional precision medicine from patient-derived xenografts
    Naim U Rashid, Daniel J Luckett, Jingxiang Chen, Michael T Lawson, Longshaokan Wang, and 6 more authors
    arXiv preprint arXiv:1912.06667, 2019
Epigenomics & Regulatory Genomics

2022

  1. Efficient detection and classification of epigenomic changes under multiple conditions
    Pedro L Baldoni, Naim U Rashid, and Joseph G Ibrahim
    Biometrics, 2022

2020

  1. Epigrahmm–epigenomic r-based analysis with hidden Markov models
    Pedro Baldoni, Naim U Rashid, and Joseph G Ibrahim
    F1000Research, 2020

2019

  1. GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer
    Samantha M Bevill, Jose F Olivares-Quintero, Noah Sciaky, Brian T Golitz, Darshan Singh, and 9 more authors
    Molecular Cancer Research, 2019
  2. Multi-omic dissection of oncogenically active epiproteomes identifies drivers of proliferative and invasive breast tumors
    John A Wrobel, Ling Xie, Li Wang, Cui Liu, Naim Rashid, and 6 more authors
    IScience, 2019
  3. Improved detection of epigenomic marks with mixed-effects hidden markov models
    Pedro L Baldoni, Naim U Rashid, and Joseph G Ibrahim
    Biometrics, 2019

2018

  1. Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues
    Yanyan Yang, Ogun Adebali, Gang Wu, Christopher P Selby, Yi-Ying Chiou, and 4 more authors
    In Proceedings of the National Academy of Sciences, 2018
  2. Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer.
    Samantha M Bevill, Noah Sciaky, Brian T Golitz, Naim U Rashid, Jon S Zawistowski, and 1 more author
    MOLECULAR CANCER RESEARCH, 2018
  3. Abstract B34: Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer
    Samantha M Bevill, Noah Sciaky, Brian T Golitz, Naim U Rashid, Jon S Zawistowski, and 1 more author
    Molecular Cancer Research, 2018

2017

  1. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex
    Jon S Zawistowski, Samantha M Bevill, Daniel R Goulet, Timothy J Stuhlmiller, Adriana S Beltran, and 20 more authors
    Cancer discovery, 2017
  2. A statistical model to assess (allele-specific) associations between gene expression and epigenetic features using sequencing data
    Naim U Rashid, Wei Sun, and Joseph G Ibrahim
    The annals of applied statistics, 2017

2016

  1. Mammalian Period represses and de-represses transcription by displacing CLOCK–BMAL1 from promoters in a Cryptochrome-dependent manner
    Yi-Ying Chiou, Yanyan Yang, Naim Rashid, Rui Ye, Christopher P Selby, and 1 more author
    In Proceedings of the National Academy of Sciences, 2016

2014

  1. Some statistical strategies for DAE-seq data analysis: variable selection and modeling dependencies among observations
    Naim Rashid, Wei Sun, and Joseph G Ibrahim
    Journal of the American Statistical Association, 2014
  2. Ongoing spontaneous DNA damage and the role of aberrant epigenome in multiple myeloma
    Maria Gkotzamanidou, Masood Shammas, Vassilis L Souliotis, Weihua Song, Jagannath Pal, and 6 more authors
    Blood, 2014

2012

  1. An integrated encyclopedia of DNA elements in the human genome.
    BE Bernstein, E Birney, I Dunham, ED Green, C Gunter, and 1 more author
    Nature, 2012

2011

  1. ZINBA integrates local covariates with DNA-seq data to identify broad and narrow regions of enrichment, even within amplified genomic regions
    Naim U Rashid, Paul G Giresi, Joseph G Ibrahim, Wei Sun, and Jason D Lieb
    Genome biology, 2011
All Publications (Chronological)

2026

  1. The ADAPT learning cancer treatment system: ARPA-H’s initiative to revolutionize cancer therapy
    Andrea H Bild, Michelle C Sangar, Jasmine A McQuerry, Trey Ideker, Scott Kopetz, and 15 more authors
    Cancer Cell, 2026

2025

  1. Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy
    Akram Yazdani, Heinz-Josef Lenz, Gianluigi Pillonetto, Raul Mendez-Giraldez, Azam Yazdani, and 18 more authors
    Communications Medicine, 2025
  2. Unsupervised Imputation of Non-Ignorably Missing Data Using Importance-Weighted Autoencoders
    David K Lim, Naim U Rashid, Junier B Oliva, and Joseph G Ibrahim
    Statistics in Biopharmaceutical Research, 2025
  3. Tumor-intrinsic kinome landscape of pancreatic cancer reveals new therapeutic approaches
    Yi Xu, Xianlu L Peng, Michael P East, Ian C McCabe, Grace C Stroman, and 16 more authors
    Cancer discovery, 2025
  4. Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)
    Aranzazu Fernandez-Martinez, Maki Tanioka, Sung Gwe Ahn, Paola Zagami, Tomás Pascual, and 18 more authors
    Annals of Oncology, 2025
  5. Efficient Computation of High‐Dimensional Penalized Piecewise Constant Hazard Random Effects Models
    Hillary M Heiling, Naim U Rashid, Quefeng Li, Xianlu L Peng, Jen Jen Yeh, and 1 more author
    Statistics in Medicine, 2025
  6. Cross-platform comparison of gene expression-based cancer molecular subtyping reveals discrepancies with exome capture methods
    Jaewon J Lee, Mohammed Aldakkak, Ashley B Morrison, Sam Z Thalji, Xianlu L Peng, and 6 more authors
    NPJ Precision Oncology, 2025
  7. Defining the MYC-regulated transcriptome and kinome that support KRAS-and ERK-dependent growth of pancreatic cancer
    Priya S Hibshman, Clint A Stalnecker, Jeffrey A Klomp, Kristina Drizyte-Miller, Jennifer E Klomp, and 19 more authors
    Science Signaling, 2025
  8. Abstract B100: Spatial relationships between tumor subtypes and tumor-promoting CAFs with clinical implications
    Xianlu Laura Peng, Ian McCabe, Elena Kharitonova, Ryan Zhao, Changfei Luan, and 15 more authors
    Cancer Research, 2025
  9. Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets
    Brooke M Felsheim, Aranzazu Fernandez-Martinez, Cheng Fan, Adam D Pfefferle, Michele C Hayward, and 7 more authors
    NPJ Breast Cancer, 2025
  10. Baseline and adaptive activated kinome profiling identifies PTK6 as a mediator of resistance to vemurafenib and dabrafenib but not encorafenib in BRAFV600-mutant metastatic melanoma
    Steve P Angus, Naim U Rashid, Andrew J Walther, David L Corcoran, Steven D Rhodes, and 15 more authors
    Cancer Research, 2025
  11. Platform and sample type independent single sample classifier for treatment decision making in pancreatic ductal adenocarcinoma cancer
    Jen Jen Yeh, Richard Moffitt, and Naim Ur Rashid
    2025
  12. Targeting pancreatic cancer stroma with vitamin D normalizes survival between fibroblast subtypes
    JJ Lee, P Chan, C Luan, EV Kharitonova, NU Rashid, and 3 more authors
    HPB, 2025

2024

  1. Tumor intrinsic subtypes and gene expression signatures in early-stage ERBB2/HER2-positive breast cancer: a pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials
    Aranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, Tomás Pascual, Katherine A Hoadley, and 16 more authors
    JAMA oncology, 2024
  2. JCO
    DNA mutational profiling in patients with colorectal cancer treated with standard of care reveals differences in outcome and racial distribution of mutations
    Federico Innocenti, Wancen Mu, Xueping Qu, Fang-Shu Ou, Omar Kabbarah, and 4 more authors
    Journal of Clinical Oncology, 2024
  3. glmmpen: High dimensional penalized generalized linear mixed models
    Hillary M Heiling, Naim U Rashid, Quefeng Li, and Joseph G Ibrahim
    The R journal, 2024
  4. Determination of permissive and restraining cancer-associated fibroblast (DeCAF) subtypes
    Xianlu Laura Peng, Elena V Kharitonova, Yi Xu, Joseph F Kearney, Changfei Luan, and 18 more authors
    bioRxiv, 2024
  5. Purity independent subtyping of tumors (PurIST) pancreatic cancer classifier: analytic validation of a 16-RNA expression signature distinguishing basal and classical subtypes
    Yan Li, Jason D Merker, Rachana Kshatriya, Dimitri G Trembath, Ashley B Morrison, and 4 more authors
    The Journal of Molecular Diagnostics, 2024
  6. Efficient computation of high-dimensional penalized generalized linear mixed models by latent factor modeling of the random effects
    Hillary M Heiling, Naim U Rashid, Quefeng Li, Xianlu L Peng, Jen Jen Yeh, and 1 more author
    Biometrics, 2024
  7. ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.
    Jose Pablo Leone, Kathryn Jean Ruddy, Naim Rashid, Sharon H Giordano, Gaorav P Gupta, and 11 more authors
    2024
  8. Tumor-intrinsic and cancer-associated fibroblast subtypes independently predict outcomes in pancreatic cancer
    Jaewon J Lee, Joseph F Kearney, Hannah E Trembath, Arthi Hariharan, Michelle E LaBella, and 9 more authors
    Annals of surgery, 2024
  9. Deeply learned generalized linear models with missing data
    David K Lim, Naim U Rashid, Junier B Oliva, and Joseph G Ibrahim
    Journal of Computational and Graphical Statistics, 2024
  10. Differential transcript usage analysis incorporating quantification uncertainty via compositional measurement error regression modeling
    Amber M Young, Scott Van Buren, and Naim U Rashid
    Biostatistics, 2024
  11. Baseline pancreatic cancer CAF subtype determines response to neoadjuvant chemotherapy
    J Lee, Y Dave, P Chan, C Luan, E Kharitonova, and 5 more authors
    PANCREAS, 2024
  12. Development of DeCAF for CAF subtyping in patient tumors
    X Peng, E Kharitonova, I Mccabe, J Kearney, J Lee, and 11 more authors
    PANCREAS, 2024
  13. Abstract A042: Clinical classification of cancer-associated fibroblast subtypes predicts prognosis and treatment response
    Xianlu L Peng, Elena V Kharitonova, Ian C McCabe, Changfei Luan, Ryan T Zhao, and 17 more authors
    Cancer Research, 2024
  14. Kinome state is predictive of cell viability in pancreatic cancer tumor and cancer-associated fibroblast cell lines
    Matthew E Berginski, Madison R Jenner, Chinmaya U Joisa, Gabriela Herrera Loeza, Brian T Golitz, and 6 more authors
    PeerJ, 2024
  15. Platform and sample type independent single sample classifier for treatment decision making in pancreatic ductal adenocarcinoma cancer
    Jen Jen Yeh, Richard Moffitt, and Naim Ur Rashid
    2024
  16. Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in HER2+ early-breast cancer (EBC)
    Aranzazu Fernandez-Martinez, Maki Tanioka, Sung Gwe Ahn, Paola Zagami, Tomas Pascual, and 17 more authors
    CANCER RESEARCH, 2024
  17. Supplementary Materials for Unsupervised Imputation of Non-ignorably Missing Data Using Importance-Weighted Autoencoders
    David K Lim, Naim U Rashid, Junier B Oliva, and Joseph G Ibrahim
    2024
  18. Combination of tumor and CAF subtypes better predict response to neoadjuvant therapy in pancreatic cancer
    Jaewon Lee, Joseph Kearney, Priscilla Chan, Elena Kharitonova, Arthi Hariharan, and 8 more authors
    ANNALS OF SURGICAL ONCOLOGY, 2024
  19. Molecular subtyping of pancreatic cancers using commercial sequencing platforms-a cautionary tale
    JJ Lee, S Thalji, AB Morrison, M Aldakkak, XL Peng, and 9 more authors
    HPB, 2024

2023

  1. Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials
    Aranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, Paolo Nuciforo, Naim U Rashid, and 14 more authors
    JAMA oncology, 2023
  2. Sub-Cluster Identification through Semi-Supervised Optimization of Rare-Cell Silhouettes (SCISSORS) in single-cell RNA-sequencing
    Jack R Leary, Yi Xu, Ashley B Morrison, Chong Jin, Emily C Shen, and 5 more authors
    Bioinformatics, 2023
  3. Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model
    Luke A Torre-Healy, Ryan R Kawalerski, Ki Oh, Lucie Chrastecka, Xianlu L Peng, and 4 more authors
    Communications Biology, 2023
  4. Association of PIK3CA mutation with pathologic complete response and outcome by hormone receptor status and intrinsic subtype in early-stage ERBB2/HER2-positive breast cancer
    Paola Zagami, Aranzazu Fernandez-Martinez, Naim U Rashid, Katherine A Hoadley, Patricia A Spears, and 3 more authors
    JAMA Network Open, 2023
  5. RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling
    Antje Schaefer, Richard G Hodge, Haisheng Zhang, G Aaron Hobbs, Julien Dilly, and 15 more authors
    Science signaling, 2023
  6. Estimating cell type composition using isoform expression one gene at a time
    Hillary M Heiling, Douglas R Wilson, Naim U Rashid, Wei Sun, and Joseph G Ibrahim
    Biometrics, 2023
  7. Abstract PD18-04: Prognostic implications of PIK3CA mutation by hormone receptor status and intrinsic subtype in early stage HER2-positive breast cancer: a correlative analysis from CALGB 40601
    Paola Zagami, Aranzazu Fernandez-Martinez, Naim U Rashid, Katherine A Hoadley, Patty Spears, and 2 more authors
    Cancer Research, 2023
  8. Supporting Information for Deeply-Learned Generalized Linear Models with Missing Data
    David K Lim, Naim U Rashid, Junier B Oliva, and Joseph G Ibrahim
    2023
  9. Impact of race and age on intrinsic subtype distribution and treatment decisions in metastatic breast cancer: Preliminary analysis of HARMONY (LCCC1829).
    Joannie M Ivory, Naim Rashid, Paola Zagami, Charles M Perou, Katherine Elizabeth Reeder-Hayes, and 1 more author
    2023

2022

  1. Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity
    Bhalchandra Mirlekar, Yan Wang, Sirui Li, Mi Zhou, Sarah Entwistle, and 10 more authors
    Cell reports Medicine, 2022
  2. Functional and biological heterogeneity of KRASQ61 mutations
    Minh V Huynh, G Aaron Hobbs, Antje Schaefer, Mariaelena Pierobon, Leiah M Carey, and 16 more authors
    Science signaling, 2022
  3. Tumor immunogenomic features determine outcomes in patients with metastatic colorectal cancer treated with standard-of-care combinations of bevacizumab and cetuximab
    Federico Innocenti, Akram Yazdani, Naim Rashid, Xueping Qu, Fang-Shu Ou, and 7 more authors
    Clinical Cancer Research, 2022
  4. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay
    DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, and 8 more authors
    Annals of Oncology, 2022
  5. Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials.
    Aranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, Tomas Pascual, Katherine A Hoadley, and 15 more authors
    2022
  6. Methods and compositions for prognostic and/or diagnostic subtyping of pancreatic cancer
    Richard Moffitt, Jen Jen Yeh, and Naim Ur Rashid
    2022
  7. Efficient detection and classification of epigenomic changes under multiple conditions
    Pedro L Baldoni, Naim U Rashid, and Joseph G Ibrahim
    Biometrics, 2022
  8. Purity independent subtyping of tumors (purist), a platform and sample type independent single sample classifier for treatment decision making in pancreatic cancer
    Jen Jen Yeh, Richard Moffitt, and Naim Ur Rashid
    2022

2021

  1. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
    DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, and 11 more authors
    Annals of Oncology, 2021
  2. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
    J Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, Priya S Hibshman, Devon R Blake, and 13 more authors
    Journal of Biological Chemistry, 2021
  3. FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
    Steven P Angus, Timothy J Stuhlmiller, Gaurav Mehta, Samantha M Bevill, Daniel R Goulet, and 25 more authors
    NPJ breast cancer, 2021
  4. High-dimensional precision medicine from patient-derived xenografts
    Naim U Rashid, Daniel J Luckett, Jingxiang Chen, Michael T Lawson, Longshaokan Wang, and 6 more authors
    Journal of the American Statistical Association, 2021
  5. Model-based feature selection and clustering of RNA-seq data for unsupervised subtype discovery
    David K Lim, Naim U Rashid, and Joseph G Ibrahim
    The annals of applied statistics, 2021
  6. Gene-expression based subtyping of pancreatic ductal adenocarcinoma
    Richard Moffitt, Jen Jen Yeh, and Naim Ur Rashid
    2021
  7. Compression of quantification uncertainty for scRNA-seq counts
    Scott Van Buren, Hirak Sarkar, Avi Srivastava, Naim U Rashid, Rob Patro, and 1 more author
    Bioinformatics, 2021
  8. Handling non-ignorably missing features in electronic health records data using importance-weighted autoencoders
    David K Lim, Naim U Rashid, Junier B Oliva, and Joseph G Ibrahim
    arXiv preprint arXiv:2101.07357, 2021
  9. Clinical application of next-generation sequencing in recurrent glioblastoma
    Daniel Zeitouni, Michael P Catalino, Jordan Wise, Sean McCabe, Kathryn Pietrosimone, and 2 more authors
    Onco, 2021
  10. Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer
    Susan Tsai, Erkut Borazanci, Margaret Gulley, Naim Rashid, Jason Merker, and 8 more authors
    Cancer Research, 2021
  11. Sub-Cluster Identification through Semi-Supervised Optimization of Rare-cell Silhouettes (SCISSORS) in Single-Cell Sequencing
    Jack Leary, Yi Xu, Ashley Morrison, Chong Jin, Emily C Shen, and 4 more authors
    bioRxiv, 2021
  12. Reply to:‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’by D. Fabrizio et al.
    Daniel James McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, and 8 more authors
    Annals of Oncology, 2021
  13. Kinome state is predictive of cell viability in pancreatic cancer tumor and stroma cell lines
    Matthew E Berginski, Madison R Jenner, Chinmaya U Joisa, Silvia G Herrera Loeza, Brian T Golitz, and 6 more authors
    BioRxiv, 2021
  14. 120MO Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials
    A Fernandez-Martinez, T Pascual, B Singh, P Nuciforo, KA Hoadley, and 9 more authors
    Annals of Oncology, 2021
  15. Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer.
    Susan Tsai, Erkut Borazanci, Margaret Gulley, Naim Rashid, Jason Merker, and 8 more authors
    CANCER RESEARCH, 2021
  16. Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer
    J Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, Devon R Blake, Priya S Hibshman, and 13 more authors
    bioRxiv, 2021
  17. Metadata record for the manuscript: FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
    Steven P Angus, Timothy J Stuhlmiller, Gaurav Mehta, Samantha M Bevill, Daniel R Goulet, and 25 more authors
    (No Title), 2021

2020

  1. CCR
    Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer
    Naim U Rashid, Xianlu L Peng, Chong Jin, Richard A Moffitt, Keith E Volmar, and 14 more authors
    Clinical Cancer Research, 2020
  2. B cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer
    Bhalchandra Mirlekar, Daniel Michaud, Samuel J Lee, Nancy P Kren, Cameron Harris, and 12 more authors
    Cancer immunology research, 2020
  3. A P53-independent DNA damage response suppresses oncogenic proliferation and genome instability
    Katerina D Fagan-Solis, Dennis A Simpson, Rashmi J Kumar, Luciano G Martelotto, Lisle E Mose, and 8 more authors
    Cell reports, 2020
  4. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy
    Matthew B Lipner, Xianlu L Peng, Chong Jin, Yi Xu, Yanzhe Gao, and 10 more authors
    JCI insight, 2020
  5. Modeling between-study heterogeneity for improved replicability in gene signature selection and clinical prediction
    Naim U Rashid, Quefeng Li, Jen Jen Yeh, and Joseph G Ibrahim
    Journal of the American Statistical Association, 2020
  6. Differential transcript usage analysis incorporating quantification uncertainty via compositional measurement error regression modeling
    Scott Van Buren, and Naim Rashid
    bioRxiv, 2020
  7. INNV-17. NEXT GENERATION SEQUENCING IMPACTS OUTCOMES IN RECURRENT PRIMARY GLIOBLASTOMA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS
    Daniel Zeitouni, Michael Catalino, Jordan Wise, Kathryn Pietrosimone, Sean McCabe, and 2 more authors
    Neuro-Oncology, 2020
  8. Supporting Information for Model-based Feature Selection and Clustering of RNA-seq Data for Unsupervised Subtype Discovery
    David K Lim, Naim U Rashid, and Joseph G Ibrahim
    2020
  9. Epigrahmm–epigenomic r-based analysis with hidden Markov models
    Pedro Baldoni, Naim U Rashid, and Joseph G Ibrahim
    F1000Research, 2020

2019

  1. Genetic determinants of cellular addiction to DNA polymerase theta
    Wanjuan Feng, Dennis A Simpson, Juan Carvajal-Garcia, Brandon A Price, Rashmi J Kumar, and 7 more authors
    Nature communications, 2019
  2. GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer
    Samantha M Bevill, Jose F Olivares-Quintero, Noah Sciaky, Brian T Golitz, Darshan Singh, and 9 more authors
    Molecular Cancer Research, 2019
  3. Next-generation sequencing (NGS) in metastatic colorectal cancer (mCRC): Novel mutated genes and their effect on response to therapy (Alliance)
    F Innocenti, N Rashid, M Wancen, F-S Ou, X Qu, and 6 more authors
    Annals of Oncology, 2019
  4. Multi-omic dissection of oncogenically active epiproteomes identifies drivers of proliferative and invasive breast tumors
    John A Wrobel, Ling Xie, Li Wang, Cui Liu, Naim Rashid, and 6 more authors
    IScience, 2019
  5. High dimensional precision medicine from patient-derived xenografts
    Naim U Rashid, Daniel J Luckett, Jingxiang Chen, Michael T Lawson, Longshaokan Wang, and 6 more authors
    arXiv preprint arXiv:1912.06667, 2019
  6. Improved detection of epigenomic marks with mixed-effects hidden markov models
    Pedro L Baldoni, Naim U Rashid, and Joseph G Ibrahim
    Biometrics, 2019
  7. Supplemental Material for “Modeling Between-Study Heterogeneity for Improved Replicability in Gene Signature Selection and Clinical Prediction”
    Naim U Rashid, Quefeng Li, Jen Jen Yeh, and Joseph G Ibrahim
    2019

2018

  1. KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism
    Angelina V Vaseva, Devon R Blake, Thomas SK Gilbert, Serina Ng, Galen Hostetter, and 16 more authors
    Cancer cell, 2018
  2. Cisplatin-DNA adduct repair of transcribed genes is controlled by two circadian programs in mouse tissues
    Yanyan Yang, Ogun Adebali, Gang Wu, Christopher P Selby, Yi-Ying Chiou, and 4 more authors
    In Proceedings of the National Academy of Sciences, 2018
  3. Stromal content is correlated with tissue site, contrast retention, and survival in pancreatic adenocarcinoma
    Robert J Torphy, Zhen Wang, Aisha True-Yasaki, Keith E Volmar, Naim Rashid, and 5 more authors
    JCO precision oncology, 2018
  4. Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer.
    Samantha M Bevill, Noah Sciaky, Brian T Golitz, Naim U Rashid, Jon S Zawistowski, and 1 more author
    MOLECULAR CANCER RESEARCH, 2018
  5. Abstract B34: Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer
    Samantha M Bevill, Noah Sciaky, Brian T Golitz, Naim U Rashid, Jon S Zawistowski, and 1 more author
    Molecular Cancer Research, 2018
  6. Relationship between body mass index (BMI) and gene expression profiles of cervical cancer in the cancer genome atlas (TCGA) project
    Arthur-Quan Tran, Stephanie Adele Sullivan, Sean Doyle McCabe, Naim Rashid, and Victoria L Bae-Jump
    Gynecologic Oncology, 2018

2017

  1. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex
    Jon S Zawistowski, Samantha M Bevill, Daniel R Goulet, Timothy J Stuhlmiller, Adriana S Beltran, and 20 more authors
    Cancer discovery, 2017
  2. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer
    Amanda ED Van Swearingen, Maria J Sambade, Marni B Siegel, Shivani Sud, Robert S McNeill, and 12 more authors
    Neuro-oncology, 2017
  3. Kinome profiling identifies druggable targets for novel human cytomegalovirus (HCMV) antivirals
    Kyle C Arend, Erik M Lenarcic, Heather A Vincent, Naim Rashid, Eric Lazear, and 7 more authors
    Molecular & Cellular Proteomics, 2017
  4. A statistical model to assess (allele-specific) associations between gene expression and epigenetic features using sequencing data
    Naim U Rashid, Wei Sun, and Joseph G Ibrahim
    The annals of applied statistics, 2017

2016

  1. Mammalian Period represses and de-represses transcription by displacing CLOCK–BMAL1 from promoters in a Cryptochrome-dependent manner
    Yi-Ying Chiou, Yanyan Yang, Naim Rashid, Rui Ye, Christopher P Selby, and 1 more author
    In Proceedings of the National Academy of Sciences, 2016
  2. Metabolic reprogramming through fatty acid transport protein 1 (FATP1) regulates macrophage inflammatory potential and adipose inflammation
    Amy R Johnson, Yuanyuan Qin, Alyssa J Cozzo, Alex J Freemerman, Megan J Huang, and 16 more authors
    Molecular metabolism, 2016
  3. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
    Rao H Prabhala, Mariateresa Fulciniti, Dheeraj Pelluru, Naim Rashid, Andreea Nigroiu, and 16 more authors
    Leukemia, 2016
  4. Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project
    Dario R Roque, Liza Makowski, Ting-Huei Chen, Naim Rashid, D Neil Hayes, and 1 more author
    Gynecologic oncology, 2016

2015

  1. Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma
    Richard A Moffitt, Raoud Marayati, Elizabeth L Flate, Keith E Volmar, S Gabriela Herrera Loeza, and 13 more authors
    Nature genetics, 2015
  2. Mu opioid splice variant MOR-1K contributes to the development of opioid-induced hyperalgesia
    Folabomi A Oladosu, Matthew S Conrad, Sandra C O’Buckley, Naim U Rashid, Gary D Slade, and 1 more author
    PloS one, 2015
  3. Trends and predictors of resection of the primary tumor for patients with stage IV colorectal cancer
    Mia Shapiro, Naim U Rashid, Edward E Whang, Valia A Boosalis, Qin Huang, and 3 more authors
    Journal of surgical oncology, 2015
  4. Functional and clinical impact of splicing factor dysregulation in multiple myeloma
    Mariateresa Fulciniti, Mehmet Kemal Samur, Naim Ur Rashid, Rajya Lakshmi Bandi, Manoj Bhasin, and 3 more authors
    Blood, 2015
  5. Radiation therapy for unresectable pancreatic adenocarcinoma: population-based trends in utilization and survival rates in the United States
    Mia Shapiro, Naim U Rashid, Qin Huang, Shira L Galper, Valia A Boosalis, and 2 more authors
    JAMA surgery, 2015

2014

  1. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
    Niccolo Bolli, Hervé Avet-Loiseau, David C Wedge, Peter Van Loo, Ludmil B Alexandrov, and 30 more authors
    Nature communications, 2014
  2. Differential and limited expression of mutant alleles in multiple myeloma
    Naim U Rashid, Adam S Sperling, Niccolo Bolli, David C Wedge, Peter Van Loo, and 13 more authors
    Blood, The Journal of the American Society of Hematology, 2014
  3. Some statistical strategies for DAE-seq data analysis: variable selection and modeling dependencies among observations
    Naim Rashid, Wei Sun, and Joseph G Ibrahim
    Journal of the American Statistical Association, 2014
  4. Alternative splicing is a frequent event and impacts clinical outcome in myeloma: a large RNA-seq data analysis of newly-diagnosed myeloma patients
    Naim Rashid, Stephane Minvielle, Florence Magrangeas, Mehmet Kemal Samur, Alice Clynen, and 10 more authors
    Blood, 2014
  5. Frequent Igh fusion transcripts with clinical impact in multiple myeloma
    Alice Cleynen, Raphael Szalat, Mehmet Kemal Samur, Naim Rashid, Giovanni Parmigiani, and 2 more authors
    Blood, 2014
  6. Functional and Clinical Relevance of Splicing Factor SRSF1 in Multiple Myeloma (MM)
    Mariateresa Fulciniti, Manoj Bhasin, Mehmet Kemal Samur, Rajya Lakshmi Bandi, Naim Rashid, and 6 more authors
    Blood, 2014
  7. Ongoing spontaneous DNA damage and the role of aberrant epigenome in multiple myeloma
    Maria Gkotzamanidou, Masood Shammas, Vassilis L Souliotis, Weihua Song, Jagannath Pal, and 6 more authors
    Blood, 2014

2013

  1. Pain modality-and sex-specific effects of COMT genetic functional variants
    Inna Belfer, Samantha K Segall, William R Lariviere, Shad B Smith, Feng Dai, and 9 more authors
    PAIN®, 2013
  2. Bone marrow microenvironment affects the pathogenesis of multiple myeloma through downregulation of alternative splicing factor FOX2 in myeloma cells
    Weihua Song, Chaolin Zhang, Yiguo Hu, Maria Gkotzamanidou, Parantu Shah, and 13 more authors
    Blood, 2013

2012

  1. An integrated encyclopedia of DNA elements in the human genome.
    BE Bernstein, E Birney, I Dunham, ED Green, C Gunter, and 1 more author
    Nature, 2012
  2. Serotonin-Induced Hypersensitivity via Inhibition of Catechol O-Methyltransferase Activity
    Douglas Tsao, Jeffrey S Wieskopf, Naim Rashid, Robert E Sorge, Rachel L Redler, and 58 more authors
    Molecular Pain, 2012

2011

  1. ZINBA integrates local covariates with DNA-seq data to identify broad and narrow regions of enrichment, even within amplified genomic regions
    Naim U Rashid, Paul G Giresi, Joseph G Ibrahim, Wei Sun, and Jason D Lieb
    Genome biology, 2011
  2. Cytokine biomarkers and chronic pain: association of genes, transcription, and circulating proteins with temporomandibular disorders and widespread palpation tenderness
    Gary D Slade, Mathew S Conrad, Luda Diatchenko, Naim U Rashid, Sheng Zhong, and 6 more authors
    Pain, 2011